Evaluation on Prognostic Ability of Serum Uric Acid for Very Old Acute Coronary Syndrome Patients with Diabetes Mellitus: A Prospective Cohort Study

Zhenhong Fu (✉ fuzhenh@126.com)

Chinese PLA General Hospital <https://orcid.org/0000-0002-2784-7629>

Yang Jiao

Chinese PLA General Hospital

Jihang Wang

Chinese PLA General Hospital

Qing Xi

Chinese PLA General Hospital

Xia Yang

Chinese PLA General Hospital

Mingzhi Shen

Chinese PLA General Hospital

Hao Xue

Chinese PLA General Hospital

Jun Guo

Chinese PLA General Hospital

Wei Dong

Chinese PLA General Hospital

Yundai Chen

Chinese PLA General Hospital

Research article

Keywords: uric acid, very old, acute coronary syndrome, diabetes mellitus, prognosis

Posted Date: April 29th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-23757/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background This study sought to evaluate the prognostic power of serum uric acid (UA) in predicting adverse events of very old acute coronary syndrome (ACS) patients with diabetes mellitus (DM).

Methods This analysis involved 718 ACS patients > 80 years old who were collected general clinical data and baseline blood biochemical indicators prospectively from January 2006 to December 2012, and these patients were classified into two groups based on DM, then followed up after discharge. Kaplan–Meier method was performed for major adverse cardiac events (MACE) rates and all-cause mortality. Multivariate Cox regression was performed to analyze the relationship between UA level and long-term clinical prognosis. Receiver operating characteristic (ROC) curve was analyzed to predict the cutoff value of UA of the very old ACS patients with DM.

Results There were 242 and 476 patients in groups DM and non-DM(NDM) and the follow-up time after discharge was 40–120 months (median: 63 months; interquartile range: 51–74 months). The differences in all-cause mortality, cardiac mortality and MACE rates in DM and NDM patients between the control group were statistically significant ($P = 0.001$). All-cause mortality, cardiac mortality and MACE incidence in DM patients with moderate and high UA level were significantly higher than those in control group ($P = 0.001$). There were statistically significant differences in long-term survival rates among the ACS groups ($P = 0.001$), and long-term survival rates decreased significantly with the increase of UA level. UA (OR = 2.106, 95%CI = 1.244–3.568, $P = 0.006$) was found to be an independent risk factor for all-cause mortality and MACE in very old ACS patients with DM. The cutoff value of UA was 353.6 $\mu\text{mol/L}$ (sensitivity: 67.4%; specificity: 65.7%). The elevation of serum UA level play an important role in predicting the development of all-cause mortality in elderly ACS patients with DM.

Conclusion Serum UA level is a strong independent predictor of long-term all-cause death and MACE in very old ACS patients with DM.

Introduction

With the aggravation of the population aging in China, cardiovascular diseases have become the leading killer threatening the life quality and life safety of residents. According to China Cardiovascular Disease Report in 2018, the population with cardiovascular diseases in China has reached up to 290 million, with cardiovascular diseases as the leading causes of death in China, including 11 million patients with coronary heart disease (CHD). ACS is clinical subtype of CHD, which is a group of clinical syndromes caused by acute myocardial ischemia. The clinical classification includes unstable angina pectoris, acute ST-segment elevation myocardial infarction (STEMI), and acute non-ST-segment elevation myocardial infarction (NSTEMI) [1]. Microcirculation disorder, type of atherosclerotic plaque, function of vascular endothelium, decrease of coronary blood flow and inflammatory response are all important mechanisms for the occurrence of ACS [2]. Old age and DM are both independent risk factors for ACS. It is reported that about 75% of patients hospitalized for CHD are associated with abnormal glucose metabolism, and the degree of coronary artery lesions is relatively severe [3, 4]. Persistent hyperglycemia in patients results in disorders of platelet structure and function, enhances aggregation and adhesion of platelets, and increases the risk of thrombosis [5]. UA is the final product of purines oxidation metabolism in human body and is excreted with urine [6]. Clinical studies illustrate that patients with CHD, hypertension, heart failure, DM, metabolic syndrome, chronic renal insufficiency and so on have high serum UA levels, and high UA in the body not only increases the risk of cardiovascular disease, but also is a risk factor for poor prognosis of these diseases [7–9]. One study shows that during a follow up of 2–3 years, with increase of serum UA level in CHD patients about 60 years old, the risk of all-cause mortality and cardiac death increases significantly [10]. Baseline serum UA level presents favorable values in evaluating and predicting the prognosis of patients with different subtypes of ACS [11–14]. In fact, hyperuricemia is closely related to DM. High UA level may lead to decreased hepatic insulin clearance rate, insulin sensitivity of target organs, and increased hepatic insulin resistance index, fasting and postprandial insulin levels [15–17]. Serum UA is an

independent risk factor and an important predictor of DM [18–20]. However, among the clinical studies on the prognosis of ACS patients with DM, there are few studies on the predictive value of UA, especially among very old people, which have not been clearly reported, and the pathophysiological mechanism has not been clarified. Our study analyzed the baseline serum UA level after admission and the incidence of main cardiovascular adverse events within 120 months after discharge of very old ACS patients, aiming to investigate whether serum UA level is an independent risk factor for the long-term prognosis of old-age ACS patients with DM.

Methods

This was a prospective cohort study conducted in Chinese People's Liberation Army (PLA) General Hospital Cardiac Center from January 2006 to December 2012. We enrolled a total of 718 patients aged over 80 years who were hospitalized for coronary angiography due to chest tightness, chest pain and other suspicious symptoms of ACS, including 509 males and 209 females, 242 diabetic patients and 476 non-diabetic patients, with an average age of 81.57 ± 2.16 years. According to the results of coronary angiograms, the subjects were divided into the control group and the research group, and the control group had normal coronary angiograms with a total of 89 patients, while the research group included 629 patients diagnosed with ACS. The patients were followed up once every 12 months after discharge to record the occurrence of MACE, including nonfatal AMI, target vessel revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]), cardiac death, and all-cause death. The main outcomes of this study were MACE and all-cause mortality (cardiovascular and non-cardiovascular cardiac or non-cardiac mortalities).

Inclusion criteria

All patients underwent coronary angiography in our hospital to confirm the diagnosis of CHD. All angiogram results were analyzed using the same image analysis software platform. The severity of coronary artery stenosis was recorded by Gensini score, and the recorders of experimental data were trained uniformly. According to the results of coronary angiogram, individualized treatment strategies were performed accordingly for all patients including intensive medicine treatment, PCI or CABG, and long-term follow-ups were performed after discharge. Our study was approved by Ethics Service Center of Chinese PLA General Hospital, and all patients signed the informed consents.

Exclusion criteria

Patients with severe valvular heart disease, pulmonary hypertension, severe liver insufficiency, rheumatism immunity diseases, malignant tumors, gout, infectious diseases, etc; taking UA lowering drugs within recent one month; or neuropsychiatric disorder prevented him from cooperating with the researcher were excluded.

Clinical data

General information (age, gender, body mass index [BMI], heart rate, blood pressure, left ventricular ejection fraction [LVEF] and Gensini score), cardiovascular risk factors (hypertension, hyperlipidemia, previous myocardial infarction [MI], previous stroke, chronic renal failure [CRF], smoking), blood biochemical index at admission (Total cholesterol [TC], triglycerides [TG], high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C], fasting blood glucose [FBG], UA, creatinine, HBA1C[glycosylated hemoglobin]), cardiovascular medication experience (aspirin, clopidogrel, beta-blocker, ACEI/ARB, statin) were recorded.

The estimated glomerular filtration rate (eGFR) was calculated by the Chinese modified Modification of Diet in Renal Disease equation:

$$\text{eGFR (mL/min/1.73 m}^2\text{)} = 175 \times \text{standardized creatinine (mg/dL)}^{-1.234} \times \text{age (year)}^{-0.179} \times 0.79 \text{ (if female)}.$$

Standardized creatinine (Scr) was calculated by the calibration equation:

Scr (mg/dL) = 0.795× (enzymatic method Scr [mg/dL]) + 0.29.

Chronic renal failure was defined as eGFR≤60 mL/min/1.73 m².

Statistical analysis

All data in this study were processed using a statistics software: Version 25.0 of SPSS software (IBM Corporation, Armonk, NY, USA). The measurement data of normal distribution were expressed as mean ± standard deviation, and if the variances were homogeneous, the t-test was used; if the variances were not homogeneous, the rank sum test was used. The measurement data of non-normal distribution were represented by medians with interquartile range (IQR). The enumeration data were expressed numerically and differences between groups were assessed using the chi-square test. Analysis of variance was used to compare data between groups. Multiple Cox proportional regression analysis (odds ratio [OR], 95% CI) was used to identify the factors associated with all-cause mortality and MACE. P < 0.05 means statistical significance of the difference.

Results

Baseline characteristics of the study subjects

Among the 718 subjects in this cohort study, a total of 629 patients diagnosed with ACS were assigned to the study group and divided into Group 1 (low UA level group) with UA level from 15.7 to 303 μmol/L including 205 patients, Group 2 (moderate UA level group) with UA level from 303.4 to 380.8 μmol/L including 209 patients and Group 3 (high UA level group) with UA level from 381.9 to 912.8 μmol/L including 215 patients according to the third equalization point of UA level. The UA level in the control group was normal, 344.2 ± 98.52 μmol/L. All patients signed written informed consents to participate in the cohort study.

The heart rate of Group 3 was higher than that of the control group. LVEF of patients with DM in Group 2 was significantly lower than that in Group 1 and in the control group (P < 0.01). TG of patients with DM in Group 3 was significantly higher than that of Group 2 (P < 0.01). In the study group, with the increase of UA level, eGFR showed a significant downward trend, and patients with DM had lower eGFR than that in patients without DM (P < 0.01), while TG (P < 0.05) and FBG (P < 0.01) levels of patients with DM were higher than those in patients without DM. There were no statistically significant differences in blood pressure, coronary artery stenosis score, combined diseases and medication status (P > 0.05) (Table 1).

Table 1
Study population: clinical characteristics in octogenarians

Characteristic, n(%)	Control group (n = 89)		Group 1 15.7–303 (n = 205)		Group 2 303.4-380.8 (n = 209)		Group 3 381.9-912.8 (n = 215)		P Value
	DM (n = 20)	Non DM (n = 69)	DM (n = 66)	Non DM (n = 139)	DM (n = 83)	Non DM (n = 126)	DM (n = 73)	Non DM (n = 142)	
General conditions									
Age (years)	82.1 ± 1.86	81.3 ± 1.73	81.3 ± 1.69	82.24 ± 2.38	81.36 ± 1.87	82.06 ± 2.28	81.98 ± 2.17	81.91 ± 2.02	0.325
Male	12	43	37	95	61	100	52	109	0.103
HR (bpm)	66.9 ± 11.5	71.88 ± 10.4	75.26 ± 13.8	74.19 ± 14.0	74.83 ± 13.3	72.07 ± 12.3	77.89 ± 14.5△△	76.20 ± 15.5	0.001
BMI (kg/m2)	24.38 ± 3.28	24.01 ± 3.96	24.38 ± 3.28	24.05 ± 3.52	25.60 ± 3.41	24.10 ± 3.06	24.30 ± 3.20	24.86 ± 3.29	0.501
SBP(mmHg)	142.5 ± 21.7	136.7 ± 17.7	141.8 ± 13.4	135.4 ± 22.6●	138.3 ± 21.9	136.5 ± 23.5	138.1 ± 24.1	135.1 ± 20.4	0.549
DBP (mmHg)	71.60 ± 14.6	72.86 ± 11.1	70.48 ± 11.6	71.06 ± 11.7	70.71 ± 12.7	72.59 ± 11.2	68.39 ± 12.1	72.39 ± 11.1●	0.006
EF (%)	60.1 ± 7.95	60.7 ± 6.58	58.1 ± 6.05	55.6 ± 13.71	54.1 ± 8.61△△##	56.6 ± 8.31	54.7 ± 11.01	53.6 ± 10.58	0.001
Gensini score	0	0	49.09 ± 39.6	50.83 ± 38.2	55.18 ± 40.8	45.84 ± 42.3	59.21 ± 42.4	60.63 ± 48.7	0.493
Risk factors									
Hypertension	17	55	55	97	75	90	63	109	0.641
Hyperlipoidemia	4	19	20	30	18	26	16	33	0.566
Previous MI	0	6	8	27	17	23	10	32	0.105
Previous stroke	5	7	10	27	21	27	18	32	0.441
CRF	2	3	7	9	14	12	15	20	0.367
Smoking	3	9	17	27	26	31	23	35	0.287
Baseline blood feature									
TC(mmol/L)	3.94 ± 1.03	3.78 ± 0.81	3.85 ± 1.03	4.05 ± 0.89	4.05 ± 1.02	4.11 ± 0.98	4.10 ± 0.88	4.24 ± 0.98	0.499
TG(mmol/L)	1.27 ± 0.56	1.17 ± 0.53	1.49 ± 0.90	1.24 ± 0.61●	1.37 ± 0.59	1.31 ± 0.67	1.72 ± 0.85▽▽	1.45 ± 0.80●	0.003

Characteristic, n(%)	Control group (n = 89)		Group 1 15.7–303 (n = 205)		Group 2 303.4–380.8 (n = 209)		Group 3 381.9–912.8 (n = 215)		P Value
HDL-C(mmol/L)	1.26 ± 0.50	1.22 ± 0.34	1.17 ± 0.33	1.23 ± 0.37	1.08 ± 0.27	1.17 ± 0.37	1.08 ± 0.47	1.12 ± 0.29	0.297
LDL-C(mmol/L)	2.07 ± 0.73	2.12 ± 0.72	2.13 ± 0.88	2.52 ± 0.77●●	2.28 ± 0.87	2.39 ± 0.82	2.26 ± 0.74	2.51 ± 0.86●	0.003
FBG(mmol/L)	6.0 ± 1.75	5.73 ± 1.58	8.53 ± 3.07△△	6.26 ± 2.18●●	7.81 ± 2.61△△	6.31 ± 2.72●●	8.20 ± 3.03△△	6.48 ± 2.62●●	0.001
HbA1C(%)	7.89 ± 2.57	6.98 ± 2.76	8.21 ± 2.71	6.87 ± 2.33●●	8.05 ± 2.32	7.08 ± 2.56●●	8.42 ± 2.18	7.12 ± 2.38●●	0.001
e-GFR (ml/min/1.73 m2)	68.56 ± 17.6	78.21 ± 16.7●	79.39 ± 20.8	77.77 ± 30.1	69.03 ± 18.5##	71.46 ± 16.0△△#	62.15 ± 20.8**▽	68.49 ± 19.9●△△**	0.002
Cardiovascular medication									
Aspirin	19	64	66	137	81	122	71	136	0.483
Clopidogrel	15	58	66△△	138	80△△	120	67△*	133	0.001
Beta-blocker	14	36	42	83	53	67	56	98	0.336
ACEI/ARB	13	42	41	71	49	59	51	76	0.559
Statin	15	64	64△△	129	74	120	66	135	0.030

Pearson correlation analysis showed that UA level were negatively correlated with eGFR ($r=-0.202$, $P = 0.002$); EF ($r=-0.139$, $P = 0.04$) in ACS patients with DM (Fig. 1A and B).

Long-term prognosis of patients

We conducted long-term follow-up of all 718 enrolled subjects, with the follow-up time of 40–120 months (median: 63 months; IQR: 51–74 months). The all-cause mortalities of the four groups with DM were 10%(2/20), 10.6%(7/66), 39.75%(33/83) and 58.9%(43/73) ($P<0.0001$) respectively. Their cardiac mortalities were 5%(1/20), 3%(2/66), 18.1%(15/83) and 42.5%(31/73) ($P<0.0001$) separately. Their MACE rates were 15%(3/20), 21.2%(14/66), 54.2%(45/83) and 65.8%(48/73) ($P<0.0001$) respectively. The all-cause mortality of the four groups without DM patients were 13.0%(9/69), 15.1%(21/139), 19.0%(24/126) and 47.9%(68/142) ($P<0.0001$). Their cardiac mortality were 1.4%(1/69), 4.3%(6/139), 9.5%(12/126) and 32.4%(46/142) ($P<0.0001$). Their MACE rates were 1.4%(9/69), 25.2%(35/139), 31.0%(39/126) and 55.6%(79/142) ($P<0.0001$). The long-term prognosis of the four groups both with and without DM patients were significantly different.

The all-cause mortalities and MACE in Group 2 with DM were significantly higher than that in Group 2 without DM patients ($P = 0.001$), and there were no significant differences in the other three groups between DM and non-DM patients for long-term prognosis.

The all-cause mortality, cardiac mortality and MACE rates in group 3 with both DM and NDM were significantly higher than those in other three groups (control group, Group 1 and Group 2) ($P<0.01$). The all-cause mortality, cardiac mortality and MACE rates in group 2 with DM were significantly higher than those in other two groups (control group and Group 1) ($P<0.01$) (Table 2).

Table 2
Long term prognosis in ACS octogenarians according to UA tertiles

Characteristic, n(%)	Control group (n = 89)		Group 1 15.7-308.6(n = 205)		Group 2 308.8-388.8(n = 209)		Group 3 389-912.8(n = 215)		P Value
	DM (n = 20)	Non DM (n = 69)	DM (n = 66)	Non DM (n = 139)	DM (n = 83)	Non DM (n = 126)	DM (n = 73)	Non DM (n = 142)	
All cause death	2	9	7	21	33 $\Delta^{\#\#}$	24 $\bullet\bullet$	43 $\Delta\Delta\nabla\nabla^{**}$	68 $\Delta\Delta\nabla\nabla^{**}$	0.000
Cardiac death	1	1	2	6	15 $\#\#$	12	31 $\Delta\Delta\nabla\nabla^{**}$	46 $\Delta\Delta\nabla\nabla^{**}$	0.000
AMI	1	0	2	5	2	4	0	0	0.433
Revascularization	0	0	5	9	10	11	5	11	0.308
MACE	3	9	14	35	45 $\Delta\Delta^{\#\#}$	39 $\bullet\bullet$	48 $\Delta\Delta^{**}$	79 $\Delta\Delta\nabla\nabla^{**}$	0.000

We analyzed the data by Kaplan–Meier survival curves, and the results showed a statistically significant difference in long-term survival in ACS patients with DM (P = 0.001). With the increase of UA level, the long-term survival rate decreased sharply, showing a significant difference (Fig. 2).

Independent risk factors affecting long-term prognosis

A Cox regression analysis was performed to determine the factors that were associated with all-cause mortality and MACE in the end of follow-up. After being adjusted for general conditions (sex, age, BMI, SBP and LVEF), risk factors (hypertension, hyperlipidemia, previous MI, stroke and CRF), and blood biochemistry indicators (TG, TC, HDL-C, LDL-C,), heart rate(OR = 1.04, 95%CI = 1.02–1.06, P = 0.001), eGFR (OR = 0.983, 95%CI = 0.965–0.998, P = 0.002), DBP (OR = 0.968, 95%CI = 0.945–0.990, P = 0.006), UA (OR = 2.106, 95%CI = 1.244–3.568, P = 0.006) were found to be independent risk factors for all-cause mortality in ACS patients with DM. Heart rate(OR = 1.03, 95%CI = 1.01–1.05, P = 0.001), UA (OR = 1.752, 95%CI = 1.068–2.876, P = 0.026) were found to be independent risk factors for MACE in ACS patients with DM.

Analyzing the all-cause mortality of the four groups, except that the all-cause mortality in the Group 2 was significantly higher than that in the NDM group (P < 0.001), the all-cause mortalities between DM patients and NDM patients in the other three groups was not significantly difference. The all-cause mortalities of DM and NDM patients in Group 3 were significantly higher than those in the other three groups (P < 0.001), and the data of DM patients in Group 2 were also significantly higher than those in the control group and Group 1 (Fig. 3).

Diagnostic powers of Uric acid for long-term all-cause death

We established respective ROC curves according to the survival and death conditions of the DM group and the NDM group (Fig. 4Aand B), and calculated the cutoff value of UA. The AUC (area under curves) of UA in DM group was 0.726 (95% CI = 0.658–0.794, P = 0.0001) and the cutoff value for all-cause mortality was 353.6 $\mu\text{mol/L}$ (sensitivity: 67.4%; specificity: 65.7%). The AUC of UA in NDM group was 0.663 (95% CI = 0.601–0.726, P = 0.0001). According to the cutoff values of UA, DM patients in the study group were divided into two groups, Group A (UA $\leq$ 353.6 $\mu\text{mol/L}$) and Group B (UA $>$ 353.6 $\mu\text{mol/L}$). The all-cause mortality rates of the two groups were 23.97%(29/121) in Group A and 53.47%(54/101) in Group B (P $\leq$ 0.001). The statistical results showed that elevated baseline of serum UA level was an independent risk factor for all-cause mortality in very old ACS patients with DM.

Discussion

ACS is a generic term for all kinds of clinical syndromes caused by acute or subacute myocardial ischemia. The main pathophysiological basis is thrombus formation secondary to coronary artery spasm or rupture of atherosclerotic plaque in coronary arteries [21–23]. Traditional risk factors of CHD include age, hypertension, DM, hyperlipidemia, and smoking [24], and as a major risk factor, DM has been widely concerned by many scholars. Studies have shown that long-term hyperglycemia leads to increased vascular endothelial permeability, abnormal expression of inflammatory factors, and thus causes the body to be in a state of high inflammatory response [25]. In addition, the hyperglycemia leads to excessive production of reactive oxygen species and decreases the activity of antioxidant enzymes, and thus causes the body to be in a state of oxidative stress [26]. All of these factors contribute to the development of coronary atherosclerosis, which ultimately leads to the occurrence of CHD. Studies illustrate that as an independent risk factor of CHD, DM has a high predictive value for the occurrence of CHD [27]. The most common type of DM is Type 2 DM. In this study, we selected elderly ACS patients with Type 2 DM as the research object, which has a good application prospect. We analyzed the general conditions and prognostic indicators of both DM and NDM patients. In the very old patients with ACS included in our study, the proportion of DM was more than one third, which was higher than 20% of the previously reported values [28].

Uric acid is the final metabolite of various purines in the body and the uric acid level of the body is affected by a variety of factors: excessive purine intake, reduced excretion, metabolic disorders, and gene mutations and so on may increase the uric acid level [29, 30]. Gertler et al firstly proposed the association between baseline serum uric acid level and CHD in 1951[31]. Since then, multiple epidemiological studies and meta-analyses shown that hyperuricemia is an independent risk factor for CHD and increases the risk of CHD. Baseline serum uric acid level is positively correlated with the incidence and severity of CHD, and for each 1 mg/dl increase in uric acid level, the patient's all-cause mortality increases by approximately 12% [32–34]. However, there is no clear report on the indicators of long-term prognosis in very old ACS patients with DM by uric acid as evaluation factor.

This study prospectively collected the clinical information of 718 very old patients with suspected ACS who were admitted due to chest tightness and chest pain, and performed 10 years follow-up. Our objective was to analyze the relationship between baseline serum uric acid level and long-term prognosis including all-cause mortality, cardiovascular death, and MACE, and the emphasis was placed on the long-term prognosis of patients with DM. The main findings of our study are as follows: 1) uric acid is a predictor of all-cause mortality and MACE in very old ACS patients with DM. 2) The ability of uric acid to predict the prognosis of these patients increases with the uric acid level rise. 3) With the extension of follow-up time, the effect of uric acid on the prognosis of these patients becomes more significant. 4) the predict power of UA was stronger in DM patients than NDM patients. In addition, we also found that in the study group, with the increase of uric acid level, Gensini score of the patients did not present significant difference, which was inconsistent with the previous reports [35, 36]. It may be related to the significant increase in the scores of coronary artery lesions in all elderly patients enrolled in this study. By comparison and analysis of all-cause mortality and MACE rate in the study group, we found that only the results of DM and NDM patients in Group 2 were different, while there was no difference in Group 3 with high uric acid. However, the long-term prognosis indicators of both DM and NDM patients in Group 3 were significantly worse than that of the other three groups. These results suggest that the impact of elevated uric acid level on the long-term prognosis of elderly ACS patients may be higher than that of diabetes.

Our results also showed that the uric acid cutoff value of elderly ACS patients with DM was 353.6 $\mu\text{mol/L}$ (sensitivity: 67.4%; specificity: 65.7%). Cox regression results showed that, after adjusting for other factors, uric acid was found to be an independent risk factor for all-cause mortality (OR = 2.106, P = 0.006) and MACE (OR = 1.752, P = 0.026) in elderly ACS patients with DM. Therefore, in clinical practice, we should not only pay attention to the traditional risk factors of CHD such as age, hypertension, hyperlipidemia, smoking, drinking, etc., but also to the uric acid level of patients, and physicians should consider the effect of drugs on uric acid metabolism of patients when prescribe.

Previous research indicated that the hyperuricemic state in the body mainly promotes the development of CHD via the following aspects: 1) Activates platelets, promotes thrombosis, and activates inflammatory mediators to reduce plaque

stability [37–39]; 2) Stimulates NADPH oxidase, leading to the abnormal structure and function of vascular endotheliocytes and affects the production of ATP, resulting in the dysfunction of vascular endotheliocytes[40–43]; 3) leads to the precipitation of urate crystals and excessive generation of oxygen free radicals, reduces the stability of plaques [44–46]. Yuichi Saito [47] et al pointed out that elevated uric acid level was closely related to vascular endothelial dysfunction in ACS patients, which may further cause poor prognosis. In addition, uric acid reduces the ability of endotheliocytes utilizing NO, activates the oxidative stress response of mitochondria and renin-angiotensin-aldosterone system (RAAS), thus increasing the incidence of cardiovascular diseases[48]. In terms of the interaction between uric acid and DM, inflammation and oxidative stress induced by high UA may further reduce insulin sensitivity and affect the expression of insulin gene in patients [49]. Uric acid increases intracellular ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), thereby directly inhibiting the insulin signaling pathway at the receptor level [50]. In ACS patients with DM, uric acid causes insulin dysfunction and abnormal glucose metabolism, promoting oxidative stress, and ultimately aggravates the damage caused by the hyperglycemia itself to cardiovascular.

In summary, with the aggravation of global aging and the increasing incidence of CHD, the population with CHD complicated with DM is increasing year by year. With developing diagnostic techniques and treatment methods, it is necessary to find appropriate commonly used predictors to evaluate the prognosis of these patients. At present, there are relatively few studies on the predictor of prognosis for the very old ACS patients with DM. This study selected large samples, performed an up-to-10-year follow-up study, and finally confirmed that uric acid was an independent risk factor for evaluating the prognosis of such patients. What's more, the uric acid test process is simple and inexpensive. Therefore, it can be used as a clinical promotion of the detection index, having a good clinical application value.

Limitations

This study had several following limitations: 1) Sample size - Although a total of 718 elderly ACS patients were included in this study, there were only 20 DM patients in the control group and 73 DM patients in the high uric acid group, which may require additional verification in these two groups; 2) this study was a single-center observational study, and the existence of selectivity bias may affect the results, which needs to be verified by multi-center studies; 3) the purpose of this study was to research the correlation between uric acid and the prognosis of elderly ACS patients with DM, but the experimental data lacked the mean data of blood glucose and uric acid during the process of following up the research subjects.

Conclusion

Baseline serum uric acid level is an independent predictor of long-term all-cause death, cardiac death, and MACE in elderly ACS patients with DM, and the accuracy of the prediction increased with the increase of uric acid level. Therefore, uric acid may become a new indicator to predict the long-term prognosis of elderly ACS patients with DM.

Abbreviations

UA

Uric acid; ACS:Acute coronary syndrome; DM:Diabetes mellitus; MACE:Major adverse cardiac events; ROC:Receiver operating characteristic; NDM:Non- diabetes mellitus; CHD:Coronary heart disease; STEMI:ST-segment elevation myocardial infarction; NSTEMI:Non-ST-segment elevation myocardial infarction; PLA:People's Liberation Army; PCI:Percutaneous coronary intervention; CABA:Coronary artery bypass grafting; BMI:Body mass index; LVEF:Left ventricular ejection fraction; MI:Myocardial infarction; CRF:Chronic renal failure; TC:Total cholesterol; TG:Triglycerides; HDL-C:High density lipoprotein cholesterol; LDL-C:Low density lipoprotein cholesterol; FBG:Fasting blood glucose; HBA1C:Glycosylated hemoglobin; ACEI:Angiotensin converting enzyme inhibitor; ARB:Angiotensin receptor blocker; eGFR:Estimated glomerular filtration rate; IQR:Interquartile range; OR:Odds ratio; RAAS:Renin-angiotensin-aldosterone system; ENPP1:Ectonucleotide pyrophosphatase/phosphodiesterase 1

Declarations

Acknowledgements

We thanked patient advisers for the information they provided.

Authors' contributions

ZH F, YD C planned the study, MZ S, H X, Y J, JH W, J G conducted a survey, Y J analyzed the data and wrote the article. ZH F, Q X, X Y, W D contributed to the drafting. All authors read and approved the final manuscript.

Funding

This study was supported by National Natural Science Foundation of China (fund numbers 81500269, 81500202, and 81570383) and Open project of National Geriatrics Clinical Medicine Research Center (fund number NCRCG-PLAGH-2019002).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments and was approved by Ethics Service Center of Chinese PLA General Hospital. Written informed consent was obtained from all participants.

Competing interests

The authors report no conflicts of interest in this work.

Consent for publication

Not applicable.

Author details

* These authors contributed equally to this paper. ¹ Department of Cardiology, the first medical center, Chinese PLA General Hospital, Beijing, China. ² National Clinical Research Center of Geriatrics Disease, Beijing, China. ³ the first medical center, Chinese PLA General Hospital, Beijing, China. ⁴ Department of Cardiology, Hainan Hospital, Chinese PLA General Hospital, Sanya, China.

References

1. Komaru Y, Takeuchi T, Suzuki L, Asano T, Urayama KY. **Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: Influence of diabetes and its management with medication.** *Journal Of Diabetes And Its Complications* 2019;107511.
2. Ruscica G, Gatto L, Romagnoli E, Di Vito L, Fabbicocchi F, Marco V, Versaci F, Di Giorgio A, Taglieri N, La Manna A, et al. Assessment of Mechanisms of Acute Coronary Syndromes and Composition of Culprit Plaques in Patients With and Without Diabetes. *JACC Cardiovasc Imaging.* 2019;12(6):1111–2.

3. Fu ZH, Xue H, Guo J, Chen L, Dong W, Gai L, Liu H, Sun Z, Chen Y. Long-term prognostic impact of cystatin C on acute coronary syndrome octogenarians with diabetes mellitus. *Cardiovascular Diabetology*. 2013;12:157.
4. Bonaca MP, Gutierrez JA, Cannon C, Giugliano R, Blazing M, Park JG, White J, Tershakovec A, Braunwald E. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. *Lancet Diabetes Endocrinol*. 2018;6(12):934–43.
5. Giustino G, Redfors B, Mehran R, Kirtane AJ, Baber U, Genereux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, et al. Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the assessment of dual antiplatelet therapy with drug-eluting stents (adapt-des) study. *Int J Cardiol*. 2017;246:20–5.
6. Maruhashi T, Hisatome I, Kihara Y, Higashi Y. Hyperuricemia and endothelial function: From molecular background to clinical perspectives. *Atherosclerosis*. 2018;278:226–31.
7. Wannamethee SG, Papacosta O, Lennon L, Whincup PH. Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study. *International Journal Of Cardiology*. 2018;252:187–92.
8. Bae MH, Lee JH, Lee SH, Park SH, Yang DH, Park HS, Cho Y, Jun JE, Chae SC. Serum uric acid as an independent and incremental prognostic marker in addition to N-terminal pro-B-type natriuretic peptide in patients with acute myocardial infarction. *Circ J*. 2011;75(6):1440–7.
9. Ndrepepa G. Uric acid and cardiovascular disease. *Clin Chim Acta*. 2018;484:150–63.
10. Wang R, Song Y, Yan Y, Ding Z: **Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis.** *Atherosclerosis* 2016, **254**:193–199.
11. Lazzeroni D, Bini M, Camaiera U, Castiglioni P, Moderato L, Bosi D, Geroldi S, Ugolotti PT, Brambilla L, Brambilla V, et al. Serum uric acid level predicts adverse outcomes after myocardial revascularization or cardiac valve surgery. *Eur J Prev Cardiol*. 2018;25(2):119–26.
12. Timoteo AT, Lousinha A, Labandeiro J, Miranda F, Papoila AL, Oliveira JA, Ferreira ML, Ferreira RC. Serum uric acid: a forgotten prognostic marker in acute coronary syndromes? *European Heart Journal- Acute Cardiovascular Care*. 2013;2(1):44–52.
13. Spiga R, Marini MA, Mancuso E, Di Fatta C, Fuoco A, Perticone F, Andreozzi F, Mannino GC, Sesti G. Uric acid is associated with inflammatory biomarkers and induces inflammation via activating the NF-kappaB signaling pathway in HEPG2 cells. *Arteriosclerosis Thrombosis Vascular Biology*. 2017;37(6):1241–9.
14. Tscharre M, Herman R, Rohla M, Hauser C, Farhan S, Freynhofer MK, Huber K, Weiss TW. Uric acid is associated with long-term adverse cardiovascular outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. *Atherosclerosis*. 2018;270:173–9.
15. Fiorentino TV, Sesti F, Succurro E, Pedace E, Andreozzi F, Sciacqua A, Hribal ML, Perticone F, Sesti G. Higher serum levels of uric acid are associated with a reduced insulin clearance in non-diabetic individuals. *Acta Diabetol*. 2018;55(8):835–42.
16. Kramer CK, von Muhlen D, Jassal SK, Barrett-Connor E. A prospective study of uric acid by glucose tolerance status and survival: the Rancho Bernardo Study. *J Intern Med*. 2010;267(6):561–6.
17. Perticone F, Sciacqua A, Perticone M, Arturi F, Scarpino PE, Quero M, Sesti G. Serum uric acid and 1-h postload glucose in essential hypertension. *Diabetes Care*. 2012;35(1):153–7.
18. Chen YY, Kao TW, Yang HF, Chou CW, Wu CJ, Lai CH, Sun YS, Wang CC, Chen WL. The association of uric acid with the risk of metabolic syndrome, arterial hypertension or diabetes in young subjects- An observational study. *Clin Chim Acta*. 2018;478:68–73.
19. Bjornstad P, Laffel L, Lynch J, El Ghormli L, Weinstock RS, Tollefsen SE, Nadeau KJ, Group TS. Elevated serum uric acid is associated with greater risk for hypertension and diabetic kidney diseases in obese adolescents with type 2

- diabetes: An observational analysis from the treatment options for type 2 diabetes in adolescents and youth (today) study. *Diabetes Care*. 2019;42(6):1120–8.
20. Keerman M, Yang F, Hu H, Wang J, Wang F, Li Z, Yuan J, Yao P, Zhang X, Guo H, et al: **Mendelian randomization study of serum uric acid levels and diabetes risk: evidence from the Dongfeng-Tongji cohort**. *BMJ Open Diabetes Research & Care* 2020, 8(1).
 21. Mani P, Puri R, Schwartz GG, Nissen SE, Shao M, Kastelein JJP, Menon V, Lincoff AM, Nicholls SJ. Association of initial and serial C-reactive protein levels with adverse cardiovascular events and death after acute coronary syndrome: A secondary analysis of the VISTA-16 trial. *JAMA Cardiology*. 2019;4(4):314–20.
 22. Cohen A, Assyag P, Boyer-Chatenet L, Cohen-Solal A, Perdrix C, Dalichampt M, Michel PL, Montalescot G, Ravaud P, Steg PG, et al. An education program for risk factor management after an acute coronary syndrome: a randomized clinical trial. *JAMA Internal Medicine*. 2014;174(1):40–8.
 23. Tsujita K, Yamanaga K, Komura N, Sakamoto K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Oka H, Nakao K, et al. Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial. *Atherosclerosis*. 2016;251:367–72.
 24. McClelland RL, Jorgensen NW, Budoff M, Blaha MJ, Post WS, Kronmal RA, Bild DE, Shea S, Liu K, Watson KE, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: Derivation in the MESA (multi-ethnic study of atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study). *J Am Coll Cardiol*. 2015;66(15):1643–53.
 25. Duan JG, Chen XY, Wang L, Lau A, Wong A, Thomas GN, Tomlinson B, Liu R, Chan JC, Leung TW, et al. Sex differences in epidemiology and risk factors of acute coronary syndrome in Chinese patients with type 2 diabetes: a long-term prospective cohort study. *PLoS One*. 2015;10(4):e0122031.
 26. Contreras-Zentella ML, Sanchez-Sevilla L, Suarez-Cuenca JA, Olguin-Martinez M, Alatraste-Contreras MG, Garcia-Garcia N, Orozco L, Hernandez-Munoz R. The role of oxidant stress and gender in the erythrocyte arginine metabolism and ammonia management in patients with type 2 diabetes. *PLOS One*. 2019;14(7):e0219481.
 27. De Rosa R, Vasa-Nicotera M, Leistner DM, Reis SM, Thome CE, Boeckel JN, Fichtlscherer S, Zeiher AM. Coronary Atherosclerotic Plaque Characteristics and Cardiovascular Risk Factors- Insights From an Optical Coherence Tomography Study. *Circ J*. 2017;81(8):1165–73.
 28. Sethi SS, Akl EG, Farkouh ME. Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials. *Curr Diab Rep*. 2012;12(3):294–304.
 29. Li LX, Wang AP, Zhang R, Li TT, Wang JW, Bao YQ, Jia WP. Decreased urine uric acid excretion is an independent risk factor for chronic kidney disease but not for carotid atherosclerosis in hospital-based patients with type 2 diabetes: a cross-sectional study. *Cardiovascular Diabetology*. 2015;14:36.
 30. Li Q, Yang Z, Lu B, Wen J, Ye Z, Chen L, He M, Tao X, Zhang W, Huang Y, et al. Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. *Cardiovascular Diabetology*. 2011;10:72.
 31. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. *Ann Intern Med*. 1951;34(6):1421–31.
 32. Braga F, Pasqualetti S, Ferraro S, Panteghini M. Hyperuricemia as risk factor for coronary heart disease incidence and mortality in the general population: a systematic review and meta-analysis. *Clin Chem Lab Med*. 2016;54(1):7–15.
 33. Purnima S, El-Aal BG. Serum uric acid as prognostic marker of coronary heart disease (CHD). *Clin Investig Arterioscler*. 2016;28(5):216–24.
 34. Jasinge E, Kularatnam GAM, Dilanthi HW, Vidanapathirana DM, Jayasena K, Chandrasiri N, Indika NLR, Ratnayake PD, Gunasekara VN, Fairbanks LD, et al. Uric acid, an important screening tool to detect inborn errors of metabolism: a case series. *BMC Research Notes*. 2017;10(1):454.

35. Wei XB, Jiang L, Liu YH, Feng D, He PC, Chen J, Yu DQ, Tan N. Serum uric acid as a simple risk factor in patients with rheumatic heart disease undergoing valve replacement surgery. *Clin Chim Acta*. 2017;472:69–74.
36. Levantesi G, Marfisi RM, Franzosi MG, Maggioni AP, Nicolosi GL, Schweiger C, Silletta MG, Tavazzi L, Tognoni G, Marchioli R. Uric acid: A cardiovascular risk factor in patients with recent myocardial infarction. *Int J Cardiol*. 2013;167(1):262–9.
37. Lai JH, Luo SF, Hung LF, Huang CY, Lien SB, Lin LC, Liu FC, Yen BL, Ho LJ. Physiological concentrations of soluble uric acid are chondroprotective and anti-inflammatory. *Sci Rep*. 2017;7(1):2359.
38. Kimura Y, Yanagida T, Onda A, Tsukui D, Hosoyamada M, Kono H. Soluble uric acid promotes atherosclerosis via AMPK (AMP-Activated Protein Kinase)-mediated inflammation. *Arteriosclerosis Thrombosis Vascular Biology*. 2020;40(3):570–82.
39. Choi YJ, Yoon Y, Lee KY, Hien TT, Kang KW, Kim KC, Lee J, Lee MY, Lee SM, Kang DH, et al. Uric acid induces endothelial dysfunction by vascular insulin resistance associated with the impairment of nitric oxide synthesis. *FASEB J*. 2014;28(7):3197–204.
40. Lai X, Yang L, Legare S, Angileri F, Chen X, Fang Q, Yang H, Zhang C, Li X, Min X, et al. Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng-Tongji Cohort. *Int J Cardiol*. 2016;224:299–304.
41. Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T. Improving cardiovascular and renal outcomes in gout: what should we target? *Nat Rev Rheumatol*. 2014;10(11):654–61.
42. Oyama J, Tanaka A, Sato Y, Tomiyama H, Sata M, Ishizu T, Taguchi I, Kuroyanagi T, Teragawa H, Ishizaka N, et al. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study. *Cardiovascular Diabetology*. 2016;15:87.
43. Grossman C, Grossman E, Goldbourt U. Uric acid variability at midlife as an independent predictor of coronary heart disease and all-cause mortality. *PLOS ONE*. 2019;14(8):e0220532.
44. El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: A review. *J Adv Res*. 2017;8(5):487–93.
45. Mogensen UM, Kober L, Jhund PS, Desai AS, Senni M, Kristensen SL, Dukat A, Chen CH, Ramires F, Lefkowitz MP, et al. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. *Eur J Heart Fail*. 2018;20(3):514–22.
46. Takayama S, Kawamoto R, Kusunoki T, Abe M, Onji M. Uric acid is an independent risk factor for carotid atherosclerosis in a Japanese elderly population without metabolic syndrome. *Cardiovascular Diabetology*. 2012;11:2.
47. Saito Y, Kitahara H, Nakayama T, Fujimoto Y, Kobayashi Y. Relation of elevated serum uric acid level to endothelial dysfunction in patients with acute coronary syndrome. *Journal of Atherosclerosis Thrombosis*. 2019;26(4):362–7.
48. Nishida Y, Takahashi Y, Susa N, Kanou N, Nakayama T, Asai S. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study. *Cardiovascular Diabetology*. 2013;12:159.
49. Verma S, Ji Q, Bhatt DL, Mazer CD, Al-Omran M, Inzucchi SE, Wanner C, Ofstad AP, Zwiener I, George JT, et al: **The association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of empagliflozin outcome.** *Diabetes Obesity & Metabolism* 2020.
50. Tassone EJ, Cimellaro A, Perticone M, Hribal ML, Sciacqua A, Andreozzi F, Sesti G, Perticone F. Uric Acid Impairs Insulin Signaling by Promoting Enpp1 Binding to Insulin Receptor in Human Umbilical Vein Endothelial Cells. *Front Endocrinol (Lausanne)*. 2018;9:98.

Figures

Figure 1

The correlation of UA between eGFR (A) and EF (B) in ACS patients with DM. Abbreviations: UA, uric acid; eGFR, estimated glomerular filtration rate; EF, eject fraction; DM, diabetes mellitus.

Figure 2

Kaplan–Meier survival curves of long-term survival rates of study group of diabetic patients

Figure 3

All-cause mortalities in four groups according to the triplicate of uric acid concentration both of DM and NON-DM patients. Notes: Con: DM 366.88 ± 114.44 , NDM 332.55 ± 86.24 (range: 105-488.8) $\mu\text{mol/L}$, group T1: NDM 252.41 ± 51.18 , DM 253.47 ± 44.66 (range: 15.7-303) $\mu\text{mol/L}$, group T2: NDM 348.57 ± 23.38 , DM 346.80 ± 22.22 (range: 303.4-380.8) $\mu\text{mol/L}$, group T3: NDM 486.47 ± 91.08 , DM 499.66 ± 100.73 (range: 381.9-912.8) $\mu\text{mol/L}$. Abbreviations: DM, diabetes mellitus; NON-DM, non-diabetes mellitus; T, tertile.

Figure 4

ROC curves of UA for discrimination between surviving and dead patients in ACS patients with DM (A) and Non-DM (B). Abbreviations: ROC, receiver operating characteristic; UA, uric acid; ACS, acute coronary syndrome; DM, diabetes mellitus; NON-DM, non-diabetes mellitus.